Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

You may also be interested in...



Not The Way You Want To Start Your Year: Inspire Cystic Fibrosis Drug Fails Late

Denufosol, a potentially disease-altering CF drug, was headed for an NDA filing later this year based on positive Phase III TIGER-1 data, but that was before the bad news from TIGER-2.

Not The Way You Want To Start Your Year: Inspire Cystic Fibrosis Drug Fails Late

Denufosol, a potentially disease-altering CF drug, was headed for an NDA filing later this year based on positive Phase III TIGER-1 data, but that was before the bad news from TIGER-2.

More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path

With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator

Related Content

Topics

UsernamePublicRestriction

Register

PS068153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel